Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hansoh Pharmaceutical Group | Hong Kong | Healthcare | Pharmaceuticals | HK$131.45B | 25.5x | 0.63 | HK$23.60 | 6.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.5% Upside | Upgrade to Pro+ | |
Shanghai Pharma Holding | Hong Kong | Healthcare | Pharmaceuticals | HK$75.87B | -1.36 | HK$11.26 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.3% Upside | Upgrade to Pro+ | ||
Innovent Biologics | Hong Kong | Healthcare | Pharmaceuticals | HK$75.27B | -53.4x | -4.44 | HK$46.20 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.5% Upside | Upgrade to Pro+ | |
Sino Biopharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$66.78B | 18.1x | 0.6 | HK$3.73 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.7% Upside | Upgrade to Pro+ | |
Shanghai Fosun Pharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$64.77B | 24.4x | -0.68 | HK$15.44 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.2% Upside | Upgrade to Pro+ | |
CSPC Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$58.20B | 10.8x | -0.67 | HK$5.06 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.1% Upside | Upgrade to Pro+ | |
Sinopharm Group Co | Hong Kong | Healthcare | Pharmaceuticals | HK$57.23B | 7.6x | -2.1 | HK$18.38 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30% Upside | Upgrade to Pro+ | |
WuXi XDC Cayman | Hong Kong | Healthcare | Pharmaceuticals | HK$53.40B | 45x | 0.68 | HK$45.70 | 2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1.6% Upside | Upgrade to Pro+ | |
Guangzhou Baiyunshan Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$46.65B | 15.4x | -0.48 | HK$17.28 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.2% Upside | Upgrade to Pro+ | |
China Resources Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$32.79B | 9.2x | 0.85 | HK$5.22 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.3% Upside | Upgrade to Pro+ | |
Asymchem Laboratories Tianjin | Hong Kong | Healthcare | Pharmaceuticals | HK$30.36B | 37x | -0.49 | HK$56.65 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.2% Upside | Upgrade to Pro+ | |
Zai Lab | Hong Kong | Healthcare | Pharmaceuticals | HK$30.27B | -13.6x | -0.59 | HK$30.85 | 11.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.1% Upside | Upgrade to Pro+ | |
3SBio | Hong Kong | Healthcare | Pharmaceuticals | HK$28.87B | 13.2x | -1.29 | HK$12.28 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -16.3% Downside | Upgrade to Pro+ | |
Shanghai Junshi Biosciences | Hong Kong | Healthcare | Pharmaceuticals | HK$27.64B | -7.5x | -0.74 | HK$15.38 | 5.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.6% Upside | Upgrade to Pro+ | |
United Laboratories Int | Hong Kong | Healthcare | Pharmaceuticals | HK$26.06B | 9.2x | 0.3 | HK$14.30 | -5.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -18.4% Downside | Upgrade to Pro+ | |
Livzon Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$24.38B | 16.1x | 7.62 | HK$27.35 | 3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.1% Upside | Upgrade to Pro+ | |
China Grand Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$21.82B | 8.8x | 0.28 | HK$6.27 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.5% Upside | Upgrade to Pro+ | |
HUTCHMED | Hong Kong | Healthcare | Pharmaceuticals | HK$20.57B | 70.4x | -1 | HK$24.40 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Simcere | Hong Kong | Healthcare | Pharmaceuticals | HK$19.68B | 24.2x | 0.12 | HK$8.03 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.9% Upside | Upgrade to Pro+ | |
China Medical System | Hong Kong | Healthcare | Pharmaceuticals | HK$19.22B | 11x | -0.34 | HK$7.91 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.4% Upside | Upgrade to Pro+ | |
Shenzhen Hepalink | Hong Kong | Healthcare | Pharmaceuticals | HK$18.15B | -115.5x | 0.6 | HK$4.58 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -19.7% Downside | Upgrade to Pro+ | |
Henlius Biotech | Hong Kong | Healthcare | Pharmaceuticals | HK$17.75B | 17.9x | 0.05 | HK$34.65 | 6.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.9% Upside | Upgrade to Pro+ | |
Cansino Biologics | Hong Kong | Healthcare | Pharmaceuticals | HK$11.75B | -22.7x | -0.39 | HK$34.10 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.4% Upside | Upgrade to Pro+ | |
China Traditional Chinese Medicine | Hong Kong | Healthcare | Pharmaceuticals | HK$10.12B | 171.5x | -8.26 | HK$2.01 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -18.1% Downside | Upgrade to Pro+ | |
SSY Group | Hong Kong | Healthcare | Pharmaceuticals | HK$9.33B | 6.9x | 0.48 | HK$3.16 | -8.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Luye Pharma Group | Hong Kong | Healthcare | Pharmaceuticals | HK$9.29B | 11.2x | 0.18 | HK$2.48 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.1% Upside | Upgrade to Pro+ | |
Yichang Hec Changjiang Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$8.37B | 4.8x | 0.11 | HK$9.53 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.9% Upside | Upgrade to Pro+ | |
Consun Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$7.40B | 7.4x | 0.67 | HK$8.95 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.7% Upside | Upgrade to Pro+ | |
Beijing Tong Ren Tang | Hong Kong | Healthcare | Pharmaceuticals | HK$7.29B | 14.8x | -0.51 | HK$8.74 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39% Upside | Upgrade to Pro+ | |
Ascletis Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$7.13B | -23.4x | 2.58 | HK$7.45 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -34.6% Downside | Upgrade to Pro+ | |
Shanghai Fudan-Zhangjiang Bio-Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$6.94B | 64.2x | -2.67 | HK$2.56 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Tong Ren Tang Tech | Hong Kong | Healthcare | Pharmaceuticals | HK$6.35B | 9.1x | 3.28 | HK$4.99 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34% Upside | Upgrade to Pro+ | |
Hbm | Hong Kong | Healthcare | Pharmaceuticals | HK$6.22B | 12.3x | 0.26 | HK$9.18 | 7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.6% Upside | Upgrade to Pro+ | |
China Shineway Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$6.11B | 5.2x | 0.23 | HK$8.05 | -8.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.1% Upside | Upgrade to Pro+ | |
Sihuan Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$5.58B | -142.4x | -1.5 | HK$0.60 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AIM Vaccine | Hong Kong | Healthcare | Pharmaceuticals | HK$5.34B | -4x | 0.03 | HK$4.21 | -6.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Beijing Luzhu Biotechnology | Hong Kong | Healthcare | Pharmaceuticals | HK$4.98B | -27.8x | -0.83 | HK$24.95 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.4% Upside | Upgrade to Pro+ | |
Shandong Boan Biotechnology | Hong Kong | Healthcare | Pharmaceuticals | HK$4.94B | 70.9x | 0.61 | HK$8.75 | -5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.8% Upside | Upgrade to Pro+ | |
VIVA Biotech Holdings | Hong Kong | Healthcare | Pharmaceuticals | HK$4.27B | -20.9x | HK$1.79 | -11.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Ocumension | Hong Kong | Healthcare | Pharmaceuticals | HK$3.97B | -8.4x | -0.49 | HK$4.98 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Shandong Xinhua Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$3.79B | 22.8x | -1.56 | HK$5.76 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Golden Throat | Hong Kong | Healthcare | Pharmaceuticals | HK$2.92B | 10.3x | -0.41 | HK$3.97 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Tycoon Gr | Hong Kong | Healthcare | Pharmaceuticals | HK$2.90B | 11.4x | 0.11 | HK$3.58 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Shanghai Pioneer Holding | Hong Kong | Healthcare | Pharmaceuticals | HK$2.78B | 16.1x | -0.85 | HK$2.35 | 11.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Antengene | Hong Kong | Healthcare | Pharmaceuticals | HK$2.51B | -7.6x | -0.19 | HK$3.46 | -9.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -65.4% Downside | Upgrade to Pro+ | |
Everest Med | Hong Kong | Healthcare | Pharmaceuticals | HK$2.44B | HK$55.50 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Jacobson Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$2.38B | 9.3x | -1.13 | HK$1.19 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Beijing Biostar Pharmaceuticals | Hong Kong | Healthcare | Pharmaceuticals | HK$2.31B | -26.6x | HK$5.34 | -3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Essex Bio-Tech | Hong Kong | Healthcare | Pharmaceuticals | HK$1.98B | 6.6x | 1.87 | HK$3.62 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 46.3% Upside | Upgrade to Pro+ | |
Cutia Therapeutics | Hong Kong | Healthcare | Pharmaceuticals | HK$1.91B | -4x | -0.04 | HK$6.21 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |